Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX) reported Q4 2025 consolidated results on April 7, 2026. Total net revenue was approximately $3.2M in Q4, up 5% sequentially and down ~8% year-over-year. For full-year 2025 net product revenue was $11.5M. Jaguar received a $16.0M up-front, non-dilutive license payment in January 2026 from Future Pak and will recognize manufacturing revenue under the U.S. license agreement.
Jaguar recorded increased R&D and operating losses, with a 2025 net loss attributable to common shareholders of $53.6M and a loss from operations of $45.9M. Nasdaq delisting proceedings remain stayed pending an April 7, 2026 hearing.
Jaguar Health (NASDAQ:JAGX) family company Napo is a silver sponsor of the April 2-4, 2026 Elite Ped-GI Congress in Abu Dhabi and is supporting an investigator-initiated proof-of-concept study of crofelemer liquid in pediatric intestinal failure (IF) patients with MVID and SBS-IF.
The study reported parenteral support (PS) reductions of 12–37% in ongoing patients treated >1 year; an abstract on long-term safety and efficacy was submitted for ESPGHAN June 2026. The global SBS/IF market is estimated at $8.0 billion by 2033.
Jaguar Health (NASDAQ:JAGX) said FDA feedback supports a protocol amendment to permit a single-blind extension of Napo's crofelemer trial in pediatric microvillus inclusion disease (MVID). The extension aims to assess longer-term clinical benefit by reducing parenteral support (PS), with dose selection by an independent DMC.
Approximately 30% of patients have completed the double-blind phase; sites include the US, Italy and UAE. Company highlighted potential for a Breakthrough Therapy designation to enable expedited pathways.
Magdalena Biosciences (JAGX), a joint venture between Jaguar and Filament, has initiated a one-month preclinical mice study to evaluate a whole leaf coca extract for appetite suppression and post-GLP-1 weight management, with research conducted in Alberta, Canada on March 16, 2026.
The coca material was supplied by Peru's ENACO with an Internationally Recognized Certificate of Compliance (IRCC) under the Nagoya Protocol. Magdalena also plans to evaluate CNS indications including ADHD under FDA botanical drug guidance.
Jaguar Health (NASDAQ:JAGX) announced that CEO Lisa Conte will present virtually at the Life Sciences Virtual Investor Forum on Thursday, March 12, 2026 at 2:00 PM Eastern. Registration is available through the conference site and a replay of the webcast will be posted after the event.
Jaguar Health (NASDAQ:JAGX) said it strengthened its balance sheet by restructuring royalty and debt obligations with affiliates of Chicago Venture Partners L.P., including extinguishing 48,212 warrants.
The deal cut royalty/debt by ~10% (~$3 million), extended a secured revolving credit maturity by three years for ~$7 million, and left no affiliate-held debt maturing before July 2026. The company said it will pursue additional restructuring and continues development of its crofelemer powder-for-oral-solution program for rare-disease intestinal failure.
Jaguar Health (NASDAQ:JAGX) received a $3.0 million payment from Future Pak after Jaguar terminated the buy-back provision in its January 2026 U.S. licensing agreement for Mytesi and Canalevia-CA1. Jaguar earlier received $16.0 million of non-dilutive capital, with $2.0 million contingent and up to $20.0 million in future milestones.
Jaguar will continue manufacturing both crofelemer products while Future Pak holds U.S. marketing rights; Jaguar targets an NDA filing for MVID in H1 2027 and is pursuing Breakthrough Therapy designation.
Jaguar Health (NASDAQ:JAGX) reminded shareholders that March 2, 2026 is the record date for its one-time Special Stock Dividend, which consists of Series O convertible preferred stock. Payment is scheduled for March 4, 2026 and will be sent automatically to eligible holders with no action required.
The company said the dividend is intended to reward shareholders and provide protection against potential dilution while Jaguar explores pathways to repay and restructure existing indebtedness. The Preferred Stock will not be transferable or listed for trading.
Jaguar Health (NASDAQ:JAGX) declared a one-time Special Stock Dividend of Series O convertible preferred stock to holders of common stock and certain warrants of record on March 2, 2026, with a payment date of March 4, 2026.
The Preferred Stock will convert to common shares at the board's election or automatically on December 31, 2026, with conversion based on market price at conversion; the board cited potential debt reduction and dilution protection as drivers.
The company highlighted clinical progress for crofelemer, including a reported up to 37% reduction in weekly parenteral support in an initial pediatric MVID patient and a planned NDA filing in 1H 2027.
Jaguar Health (NASDAQ:JAGX) received an initial $16M payment from a US out-license of Mytesi and Canalevia-CA1, with up to $22M more tied to milestones. The company is refocusing on crofelemer for intestinal failure (SBS-IF and MVID), holding Orphan Drug Designation in the US and EU. Investigator-initiated proof-of-concept results showed parenteral support (PS) reductions of 12–37% in pediatric patients. Jaguar expects its placebo-controlled Phase 2 to complete in Q2 2026 and targets NDA-ready data in 12–18 months. Management presented at the Sequire Investor Summit on January 22, 2026.